These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7772645)

  • 61. Cortisol changes in long-term lithium therapy.
    Smigan L; Perris C
    Neuropsychobiology; 1984; 11(4):219-23. PubMed ID: 6436729
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Placebo-controlled study of tianeptine in major depressive episodes.
    Costa e Silva JA; Ruschel SI; Caetano D; Rocha FL; da Silva Lippi JR; Arruda S; Ozun M
    Neuropsychobiology; 1997; 35(1):24-9. PubMed ID: 9018020
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
    Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R
    World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat.
    Rogóz Z; Budziszewska B; Kubera M; Basta-Kaim A; Jaworska-Feil L; Skuza G; Lasoń W
    J Physiol Pharmacol; 2005 Mar; 56(1):49-61. PubMed ID: 15795475
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aminoglutethimide in treatment of metastatic breast carcinoma.
    Smith IE; Fitzharris BM; McKinna JA; Fahmy DR; Nash AG; Neville AM; Gazet JC; Ford HT; Powles TJ
    Lancet; 1978 Sep; 2(8091):646-9. PubMed ID: 80576
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Method for prediction of serum lithium levels.
    Alda M
    Biol Psychiatry; 1988 Jun; 24(2):218-24. PubMed ID: 3134057
    [TBL] [Abstract][Full Text] [Related]  

  • 68. General behavior inventory: measurement of subclinical changes during depression and lithium prophylaxis.
    Goodnick PJ; Fieve RR; Peselow E; Schlegel A; Filippi A
    Acta Psychiatr Scand; 1986 May; 73(5):529-32. PubMed ID: 3751658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differentiation of psychotic from nonpsychotic depression by a biological marker.
    Waziri R; Mott J; Wilcox J
    J Affect Disord; 1985 Sep; 9(2):175-80. PubMed ID: 2932492
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.
    Price LH; Malison RT; McDougle CJ; Pelton GH
    CNS Drugs; 1996 May; 5(5):311-20. PubMed ID: 26071044
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).
    McAllister-Williams RH; Smith E; Anderson IM; Barnes J; Gallagher P; Grunze HC; Haddad PM; House AO; Hughes T; Lloyd AJ; McColl EM; Pearce SH; Siddiqi N; Sinha B; Speed C; Steen IN; Wainright J; Watson S; Winter FH; Ferrier IN
    BMC Psychiatry; 2013 Aug; 13():205. PubMed ID: 23914988
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hormone treatment of depression.
    Joffe RT
    Dialogues Clin Neurosci; 2011; 13(1):127-38. PubMed ID: 21485752
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic options for treatment-resistant depression.
    Shelton RC; Osuntokun O; Heinloth AN; Corya SA
    CNS Drugs; 2010 Feb; 24(2):131-61. PubMed ID: 20088620
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?
    Kling MA; Coleman VH; Schulkin J
    Depress Anxiety; 2009; 26(7):641-9. PubMed ID: 19133699
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Psychotic major depression: a benefit-risk assessment of treatment options.
    Tyrka AR; Price LH; Mello MF; Mello AF; Carpenter LL
    Drug Saf; 2006; 29(6):491-508. PubMed ID: 16752932
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [New developments in pharmacotherapy of depression].
    Rupprecht R; Baghai TC; Möller HJ
    Nervenarzt; 2004 Mar; 75(3):273-80. PubMed ID: 15021929
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Crossroads of corticotropin releasing hormone, corticosteroids and monoamines. About a biological interface between stress and depression.
    Van Praag HM
    Neurotox Res; 2002; 4(5-6):531-555. PubMed ID: 12754165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.
    Schüle C; Baghai T; Zwanzger P; Ella R; Eser D; Padberg F; Möller HJ; Rupprecht R
    Psychopharmacology (Berl); 2003 Mar; 166(3):271-5. PubMed ID: 12552362
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic and therapeutic advances in treatment-resistant mood disorders.
    Blinder BJ; Bloom AR
    West J Med; 1996 Mar; 164(3):258-9. PubMed ID: 8775941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.